Parma Community General Hospital Association
Parma Community General Hospital Association was paid $15.68M by Medicaid between Jan 2018 and Dec 2024, across 283 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
PARMA, OH 44129
Next to other General Acute Care Hospital providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,681 | $1.21M | |
| 2019 | 32,715 | $1.12M | |
| 2020 | 17,128 | $855K | |
| 2021 | 26,670 | $1.21M | |
| 2022 | 34,847 | $1.47M | |
| 2023 | 169,031 | $5.47M | |
| 2024incomplete | 136,233 | $4.35M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 28,445 | 26,334 | $3.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 15,280 | 13,734 | $1.88M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 10% | 7,409 | 5,313 | $1.59M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.3% | 13,279 | 11,462 | $1.46M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.9% | 3,619 | 2,836 | $919K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.8% | 3,611 | 2,972 | $755K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.3% | 5,236 | 4,618 | $525K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 2,431 | 1,955 | $496K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.9% | 6,484 | 2,545 | $461K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.7% | 4,702 | 3,896 | $421K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 955 | 819 | $206K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 854 | 692 | $192K |
271 more codes
| 80053 | Comprehensive metabolic panel | 1.2% | 26,744 | $187K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 924 | $179K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 923 | $172K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.0% | 710 | $160K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.0% | 226 | $160K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 397 | $146K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,133 | $146K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,630 | $129K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 930 | $117K |
| 62323 | <1% | 310 | $117K | |
| G0378 | Hospital observation service, per hour | <1% | 1,877 | $95K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 593 | $94K |
| 97161 | <1% | 1,594 | $72K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,359 | $71K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 769 | $70K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,310 | $64K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 592 | $62K |
| 92550 | <1% | 657 | $57K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 701 | $54K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,589 | $53K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 514 | $48K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 628 | $47K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 434 | $46K |
| 97113 | <1% | 620 | $45K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,300 | $44K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,319 | $44K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 521 | $41K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,718 | $37K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,248 | $37K |
| 71250 | <1% | 446 | $37K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,098 | $35K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,417 | $34K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,428 | $34K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 98 | $34K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,655 | $33K |
| 92557 | <1% | 786 | $31K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 697 | $30K |
| 84484 | <1% | 8,996 | $27K | |
| 93971 | <1% | 422 | $26K | |
| 97165 | <1% | 604 | $25K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,731 | $23K |
| 85027 | <1% | 6,077 | $22K | |
| 93017 | <1% | 287 | $21K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,140 | $20K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 45 | $20K |
| 76770 | <1% | 117 | $18K | |
| 82805 | <1% | 869 | $18K | |
| 76830 | Ultrasound, transvaginal | <1% | 563 | $16K |
| 86850 | <1% | 1,046 | $15K | |
| 76642 | <1% | 161 | $13K | |
| 72131 | <1% | 399 | $13K | |
| 73562 | <1% | 291 | $13K | |
| 73630 | <1% | 729 | $12K | |
| 74018 | <1% | 458 | $12K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 42 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,567 | $11K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,104 | $11K |
| 73030 | <1% | 550 | $10K | |
| 95811 | <1% | 13 | $10K | |
| 20610 | <1% | 78 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,315 | $9K |
| 80320 | <1% | 649 | $9K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,227 | $9K |
| 83605 | <1% | 3,256 | $9K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 698 | $8K |
| 86900 | <1% | 1,095 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,273 | $8K |
| 76536 | <1% | 80 | $7K | |
| 82947 | <1% | 4,613 | $7K | |
| 12001 | <1% | 48 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 428 | $7K |
| 73130 | <1% | 584 | $7K | |
| 73610 | <1% | 578 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,908 | $7K |
| 97116 | <1% | 264 | $6K | |
| 83735 | <1% | 4,971 | $6K | |
| 73110 | <1% | 339 | $6K | |
| 85610 | <1% | 4,210 | $5K | |
| 96368 | <1% | 4,427 | $5K | |
| 96367 | <1% | 162 | $5K | |
| 93970 | <1% | 46 | $5K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 55 | $5K |
| 73502 | <1% | 280 | $5K | |
| 90715 | <1% | 347 | $5K | |
| 72100 | <1% | 269 | $5K | |
| 80061 | Lipid panel | <1% | 699 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,615 | $5K |
| 64483 | <1% | 14 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 659 | $4K |
| 96376 | <1% | 1,506 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $4K |
| 31575 | <1% | 16 | $4K | |
| 81001 | <1% | 8,376 | $4K | |
| 73560 | <1% | 181 | $4K | |
| 86140 | <1% | 515 | $4K | |
| 31231 | <1% | 13 | $3K | |
| 0002A | <1% | 95 | $3K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 97 | $3K |
| 81003 | <1% | 4,795 | $3K | |
| 99152 | <1% | 235 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,538 | $3K |
| J3490 | Unclassified drugs | <1% | 1,925 | $3K |
| 70486 | <1% | 121 | $3K | |
| 73564 | <1% | 276 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 127 | $3K |
| 0001A | <1% | 91 | $2K | |
| 86901 | <1% | 1,095 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 16 | $2K |
| 99401 | <1% | 25 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $2K |
| 76000 | <1% | 47 | $2K | |
| 84702 | <1% | 1,464 | $2K | |
| 70496 | <1% | 16 | $2K | |
| 83880 | <1% | 1,484 | $2K | |
| 80069 | <1% | 277 | $2K | |
| 93975 | <1% | 16 | $2K | |
| 12011 | <1% | 12 | $2K | |
| 72128 | <1% | 128 | $2K | |
| 81025 | <1% | 5,309 | $2K | |
| 82607 | <1% | 96 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 64 | $2K |
| 83690 | <1% | 4,383 | $1K | |
| 82728 | <1% | 92 | $1K | |
| 92523 | <1% | 18 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 379 | $1K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 70 | $1K |
| 80143 | <1% | 1,319 | $1K | |
| 82077 | <1% | 1,244 | $1K | |
| 72170 | <1% | 140 | $1K | |
| 87081 | <1% | 171 | $1K | |
| 83540 | <1% | 109 | $1K | |
| 85018 | <1% | 750 | $943.70 | |
| 85379 | <1% | 875 | $941.81 | |
| 87077 | <1% | 491 | $924.33 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,423 | $904.80 |
| 85007 | <1% | 320 | $858.60 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 245 | $827.98 |
| 87186 | <1% | 781 | $818.98 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,815 | $811.27 |
| 80076 | <1% | 485 | $807.62 | |
| 83550 | <1% | 88 | $791.12 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 750 | $702.73 |
| 87040 | <1% | 918 | $688.33 | |
| 00731 | <1% | 270 | $682.71 | |
| 85730 | <1% | 1,248 | $663.44 | |
| 87634 | <1% | 120 | $615.22 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 214 | $589.76 |
| 77061 | <1% | 13 | $571.54 | |
| 46083 | <1% | 14 | $570.48 | |
| 87631 | <1% | 26 | $568.44 | |
| 85014 | <1% | 109 | $562.05 | |
| 93296 | <1% | 24 | $555.16 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,742 | $535.93 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,346 | $532.47 |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13 | $528.71 |
| 80179 | <1% | 1,302 | $526.70 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 215 | $516.85 |
| 87075 | <1% | 823 | $516.10 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,388 | $510.74 |
| 87070 | <1% | 355 | $508.26 | |
| 84439 | <1% | 42 | $488.27 | |
| 82248 | <1% | 344 | $487.46 | |
| A9270 | Non-covered item or service | <1% | 8,693 | $480.36 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 259 | $479.88 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 750 | $478.79 |
| 0004A | <1% | 12 | $464.12 | |
| 72040 | <1% | 13 | $439.84 | |
| 80164 | <1% | 30 | $436.92 | |
| 73140 | <1% | 17 | $436.10 | |
| 82746 | <1% | 49 | $409.19 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,322 | $359.45 |
| 77065 | Tomosynthesis, mammo | <1% | 15 | $342.69 |
| 88142 | <1% | 29 | $339.42 | |
| 84132 | <1% | 599 | $333.22 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 63 | $330.62 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 33 | $313.28 |
| 87800 | <1% | 104 | $297.12 | |
| 82330 | <1% | 445 | $291.75 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,269 | $287.19 |
| 84100 | <1% | 143 | $284.64 | |
| 87205 | <1% | 331 | $266.05 | |
| 80329 | <1% | 116 | $263.25 | |
| 76801 | <1% | 13 | $256.50 | |
| 82550 | <1% | 207 | $229.56 | |
| J1815 | Injection, insulin, per 5 units | <1% | 180 | $218.78 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 269 | $211.44 |
| J2704 | Injection, propofol, 10 mg | <1% | 7,516 | $207.05 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 65 | $197.07 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,143 | $193.17 |
| G0404 | Electrocardiogram, routine ecg with 12 leads; tracing only, without interpretation and report, performed as a screening for the initial preventive physical examination | <1% | 81 | $185.52 |
| 82140 | <1% | 37 | $177.40 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 558 | $177.13 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 4,600 | $168.49 |
| 85652 | <1% | 263 | $167.88 | |
| 82150 | <1% | 177 | $163.90 | |
| 84481 | <1% | 12 | $158.10 | |
| 82570 | <1% | 101 | $151.73 | |
| 82435 | <1% | 401 | $150.94 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 880 | $124.38 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,575 | $112.85 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 564 | $109.81 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 257 | $104.70 |
| 94761 | <1% | 615 | $104.23 | |
| 73090 | <1% | 14 | $101.26 | |
| 84295 | <1% | 400 | $87.89 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,072 | $70.97 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 852 | $66.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 868 | $61.73 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,454 | $60.57 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 394 | $57.07 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 99 | $49.35 |
| 86308 | <1% | 20 | $47.57 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 341 | $44.42 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 160 | $44.11 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 673 | $41.60 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,073 | $37.91 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,078 | $37.63 |
| 87210 | <1% | 72 | $36.14 | |
| 86403 | <1% | 127 | $32.29 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,319 | $31.28 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 157 | $30.90 |
| 82010 | <1% | 17 | $28.47 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 145 | $28.18 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 114 | $22.06 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,535 | $19.87 |
| A4217 | Sterile water/saline, 500 ml | <1% | 370 | $19.86 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 136 | $17.20 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 16 | $15.59 |
| 80305 | <1% | 214 | $14.70 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 179 | $14.35 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 482 | $13.05 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 122 | $10.92 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 133 | $7.74 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 279 | $7.32 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 113 | $7.30 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 232 | $6.27 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 14 | $5.56 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 18 | $5.20 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 213 | $2.56 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 31 | $2.26 |
| 91300 | <1% | 233 | $1.87 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 113 | $0.34 |
| 3008F | 0% | 109 | $0.00 | |
| C1769 | Guide wire | 0% | 166 | $0.00 |
| 1036F | 0% | 63 | $0.00 | |
| 76377 | 0% | 93 | $0.00 | |
| 94760 | 0% | 120 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 704 | $0.00 |
| 84075 | 0% | 30 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 16 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 54 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 18 | $0.00 |
| 00813 | 0% | 24 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 482 | $0.00 |
| 84460 | 0% | 30 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 204 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 32 | $0.00 |
| 29125 | 0% | 21 | $0.00 | |
| 84450 | 0% | 30 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 75 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 15 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 44 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 25 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 45 | $0.00 |
| 84155 | 0% | 30 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 18 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 30 | $0.00 |
| 77003 | 0% | 19 | $0.00 | |
| 0753T | 0% | 19 | $0.00 | |
| 82247 | 0% | 30 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.